在患有晚期胃腺癌的患者中,尼沃卢马布诱导的胆胸
Youssef Hayssam Sultan1, Radwan Zeidan2, Mohammed Abdallah2
1Resident of Internal Medicine, University of Balamand, Beirut, Lebanon.
胆胸,尼沃卢马布治疗的罕见并发症,可能发生在胃腺癌患者. 区分这种与免疫相关的事件与恶性瘤需要仔细的临床评估.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 胆胸部涉及积在腔空间,导致呼吸问题.
- 胃腺癌和尼沃卢马布是胆胸瘤的罕见原因.
- 尼沃卢马布诱导的胆胸的机制尚未完全理解,但可能涉及免疫介导的淋巴透性.
研究的目的:
- 在接受尼沃卢马布的胃腺癌患者中报告一个独特的胆胸病例.
- 讨论区分免疫相关胆胸病与恶性输液的挑战.
主要方法:
- 病例报告详细介绍了一名患有胃腺癌和胆胸腺瘤的患者在nivolumab治疗期间.
- 对临床表现,诊断结果和治疗反应的审查.
主要成果:
- 在治疗胃腺癌的nivolumab治疗期间,患者提供了基洛托拉克斯.
- 这一案例凸显了这种不良事件的罕见性.
结论:
- 胆胸可能是与nivolumab相关的罕见免疫相关的不良事件.
- 区分恶性胆胸和免疫相关的不良事件是具有挑战性的.
- 阴性多细胞学,没有胸管阻塞,对免疫治疗的反应有助于诊断和指导关于免疫治疗的继续或中止的治疗决策.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Pneumothorax-II
Clinical Manifestations:
